Incidence of campylobacter and salmonella infections following first prescription for PPI: a cohort study using routine data

Brophy, Sinead, Jones, Kerina H., Rahman, Muhammad A., Zhou, Shang-Ming, John, Ann, Atkinson, Mark D., Francis, Nicholas Andrew ORCID: https://orcid.org/0000-0001-8939-7312, Lyons, Ronan A. and Dunstan, Frank David John ORCID: https://orcid.org/0000-0002-1043-5281 2013. Incidence of campylobacter and salmonella infections following first prescription for PPI: a cohort study using routine data. The American Journal of Gastroenterology 108 (7) , pp. 1094-1100. 10.1038/ajg.2013.30

Full text not available from this repository.

Abstract

OBJECTIVES: To examine the incidence of Campylobacter and Salmonella infection in patients prescribed proton pump inhibitors (PPIs) compared with controls. METHODS: Retrospective cohort study using anonymous general practitioner (GP) data. Anonymised individual-level records from the Secure Anonymised Information Linkage (SAIL) system between 1990 and 2010 in Wales were selected. Data were available from 1,913,925 individuals including 358,938 prescribed a PPI. The main outcome measures examined included incidence of Campylobacter or Salmonella infection following a prescription for PPI. RESULTS: The rate of Campylobacter and Salmonella infections was already at 3.1–6.9 times that of non-PPI patients even before PPI prescription. The PPI group had an increased hazard rate of infection (after prescription for PPI) of 1.46 for Campylobacter and 1.2 for Salmonella, compared with baseline. However, the non-PPI patients also had an increased hazard ratio with time. In fact, the ratio of events in the PPI group compared with the non-PPI group using the prior event rate ratio was 1.17 (95% CI 0.74–1.61) for Campylobacter and 1.00 (0.5–1.5) for Salmonella. CONCLUSIONS: People who go on to be prescribed PPIs have a greater underlying risk of gastrointestinal (GI) infection beforehand and they have a higher prevalence of risk factors before PPI prescription. The rate of diagnosis of infection is increasing with time regardless of PPI use, and there is no evidence that PPI is associated with an increase in diagnosed GI infection. It is likely that factors associated with the demographic profile of the patient are the main contributors to increased rate of GI infection for patients prescribed PPIs.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Publisher:	Nature Publishing Group
ISSN:	0002-9270
Last Modified:	24 Oct 2022 11:43
URI:	https://orca.cardiff.ac.uk/id/eprint/49135

Citation Data

Cited 44 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item